Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 15/20 | 0.62 |
| ▸ | TP53 | P04637 | 9/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11809804 | 0.89 | LMNA (0.67) | LMNAMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL28537824 | 0.86 | MAPT (0.56) | LMNAMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL11814051 | 0.85 | LMNA (0.70) | LMNAMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL2997027 | 0.85 | MAPT (0.72) | LMNAMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL15283682 | 0.85 | MAPT (0.50) | LMNAMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL12091655 | 0.83 | MAPT (0.60) | LMNAMAPTTP53THRBPOLB | |
| SCHEMBL11816949 | 0.82 | LMNA (0.55) | LMNAMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL2997341 | 0.79 | MAPT (0.59) | LMNAMAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL12091797 | 0.79 | PLAUR (0.49) | LMNAMAPTTP53THRBPOLB | |
| SCHEMBL3000546 | 0.78 | MAPT (0.44) | LMNAMAPTTP53THRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-3968121-A | 1,2-Diphenyl-4,5,6,7-tetrahydroindoles | STERLING DRUG INC. (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | PSEN2, PSEN1, CLN6 | LMNA 1067/4885MAPT 28/4885TP53 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.